Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) Enterprise Value: ¥1,552.1 Mil (As of Jul. 12, 2026) ***


BJSE:920367 Jiangxi Xinganjiang Pharmaceutical Co Ltd BJSE:920367
60 GF Score
Price ¥24.45
GF Value ¥12.09
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Jiangxi Xinganjiang Pharmaceutical Co Enterprise Value?

Jiangxi Xinganjiang Pharmaceutical Co BJSE:920367 60 Enterprise Value is ¥1,552.1 Mil as of Jul. 12, 2026. GuruFocus rates BJSE:920367 with a GF Score™ of 60/100 and a GF Value™ of ¥12.09 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Jiangxi Xinganjiang Pharmaceutical Co's Enterprise Value is ¥1,552.1 Mil. Jiangxi Xinganjiang Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ¥11.1 Mil. Therefore, Jiangxi Xinganjiang Pharmaceutical Co's EV-to-EBIT ratio for today is 140.35.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Jiangxi Xinganjiang Pharmaceutical Co's Enterprise Value is ¥1,552.1 Mil. Jiangxi Xinganjiang Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ¥11.1 Mil. Therefore, Jiangxi Xinganjiang Pharmaceutical Co's EV-to-EBITDA ratio for today is 140.35.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Jiangxi Xinganjiang Pharmaceutical Co's Enterprise Value is ¥1,552.1 Mil. Jiangxi Xinganjiang Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ¥142.6 Mil. Therefore, Jiangxi Xinganjiang Pharmaceutical Co's EV-to-Revenue ratio for today is 10.88.

EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations. As of today, Jiangxi Xinganjiang Pharmaceutical Co's Enterprise Value is ¥1,552.1 Mil. Jiangxi Xinganjiang Pharmaceutical Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was ¥22.4 Mil. Therefore, Jiangxi Xinganjiang Pharmaceutical Co's EV-to-OCF ratio for today is 69.23.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Jiangxi Xinganjiang Pharmaceutical Co's Enterprise Value is ¥1,552.1 Mil. Jiangxi Xinganjiang Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-52.1 Mil. Therefore, Jiangxi Xinganjiang Pharmaceutical Co's EV-to-FCF ratio for today is -29.76.

*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.


Jiangxi Xinganjiang Pharmaceutical Co  (BJSE:920367) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Jiangxi Xinganjiang Pharmaceutical Co's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1552.092/11.059
=140.35

Jiangxi Xinganjiang Pharmaceutical Co's current Enterprise Value is ¥1,552.1 Mil.
Jiangxi Xinganjiang Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥11.1 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Jiangxi Xinganjiang Pharmaceutical Co's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=1552.092/11.059
=140.35

Jiangxi Xinganjiang Pharmaceutical Co's current Enterprise Value is ¥1,552.1 Mil.
Jiangxi Xinganjiang Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥11.1 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Jiangxi Xinganjiang Pharmaceutical Co's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1552.092/142.607
=10.88

Jiangxi Xinganjiang Pharmaceutical Co's current Enterprise Value is ¥1,552.1 Mil.
Jiangxi Xinganjiang Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥142.6 Mil.

4. EV-to-OCF is calculated as Enterprise Value divided by its Cash Flow from Operations.

Jiangxi Xinganjiang Pharmaceutical Co's EV-to-OCF for today is:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=1552.092/22.42
=69.23

Jiangxi Xinganjiang Pharmaceutical Co's current Enterprise Value is ¥1,552.1 Mil.
Jiangxi Xinganjiang Pharmaceutical Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥22.4 Mil.

5. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

Jiangxi Xinganjiang Pharmaceutical Co's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1552.092/-52.148
=-29.76

Jiangxi Xinganjiang Pharmaceutical Co's current Enterprise Value is ¥1,552.1 Mil.
Jiangxi Xinganjiang Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-52.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jiangxi Xinganjiang Pharmaceutical Co Enterprise Value Related Terms


Jiangxi Xinganjiang Pharmaceutical Co Enterprise Value Historical Data

* Premium members only.

The historical data trend for Jiangxi Xinganjiang Pharmaceutical Co's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangxi Xinganjiang Pharmaceutical Co Enterprise Value Chart

Jiangxi Xinganjiang Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 888.42 728.75 1,205.49

Jiangxi Xinganjiang Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,488.14 1,592.00 1,519.84 1,205.49 1,102.83

BJSE:920367 vs ZTS, UTHR: Enterprise Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jiangxi Xinganjiang Pharmaceutical Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangxi Xinganjiang Pharmaceutical Co Enterprise Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jiangxi Xinganjiang Pharmaceutical Co's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Jiangxi Xinganjiang Pharmaceutical Co's Enterprise Value falls into.


BJSE:920367
60GF Score
Jiangxi Xinganjiang Pharmaceutical Co Ltd BJSE:920367
Enterprise Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangxi Xinganjiang Pharmaceutical Co Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Jiangxi Xinganjiang Pharmaceutical Co's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as

Jiangxi Xinganjiang Pharmaceutical Co's Enterprise Value for the quarter that ended in Mar. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Enterprise Value →
What does a Enterprise Value of ¥1,552.1 Mil mean?
Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) has a Enterprise Value of ¥1,552.1 Mil as of Jul. 12, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Jiangxi Xinganjiang Pharmaceutical Co and its competitors.
Is Jiangxi Xinganjiang Pharmaceutical Co's Enterprise Value too high?
Jiangxi Xinganjiang Pharmaceutical Co's current Enterprise Value is ¥1,552.1 Mil. Overall, Jiangxi Xinganjiang Pharmaceutical Co has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jiangxi Xinganjiang Pharmaceutical Co's Enterprise Value compare to ZTS and UTHR?
Jiangxi Xinganjiang Pharmaceutical Co's Enterprise Value of ¥1,552.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Jiangxi Xinganjiang Pharmaceutical Co and its competitors. Jiangxi Xinganjiang Pharmaceutical Co's current Enterprise Value is ¥1,552.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangxi Xinganjiang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥12.09, compared to a current price of ¥24.45 — trading 102.2% above its estimated fair value. The current Enterprise Value is ¥1,552.1 Mil. Jiangxi Xinganjiang Pharmaceutical Co's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367), the current Enterprise Value is ¥1,552.1 Mil as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangxi Xinganjiang Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥24.45 is trading 102.2% above its estimated GF Value™ of ¥12.09. GuruFocus considers Jiangxi Xinganjiang Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for BJSE:920367:

  • Enterprise Value: ¥1,552.1 Mil
  • GF Value™: ¥12.09 vs. price of ¥24.45 (102.2% above fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the BJSE:920367 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jiangxi Xinganjiang Pharmaceutical Co Business Description

Address No. 36 Yunzhang Road, Industrial Park, Jizhou District, Jiangxi Province, Ji'an City, CHN, 343000
Jiangxi Xinganjiang Pharmaceutical Co Ltd conducts research and development, production, and sales of chemical raw materials, chemical preparations, and Chinese patent medicines. The company's raw material medicine products are mainly calcium gluconate, zinc gluconate, ferrous gluconate, and other gluconate series raw material medicines. Its main chemical preparations are vitamin C chewable tablets and compound Yinqiao aminomin capsules, and Phenaminokamin Tablets.
60GF Score

Get the complete analysis for BJSE:920367

Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥24.45
Price
¥12.09
GF Value